+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Antibiotic Resistance Market Size, Share, & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 80 Pages
  • July 2025
  • Region: United States
  • Grand View Research
  • ID: 6154629
Description Jump to:

U.S. Antibiotic Resistance Market Summary

The U.S. antibiotic esistance market size was estimated at USD 3.09 billion in 2024 and is projected to reach USD 3.99 billion by 2030, growing at a CAGR of 4.4% from 2025 to 2030. The market is expected to grow, driven by the rising misuse and overuse of antibiotics.

According to the CDC, more than 2.8 million antimicrobial-resistant infections are reported every year in the U.S., leading to 35,000 deaths. Moreover, the rise of public health concerns and the need for new antibiotic therapies are expected to drive market growth. According to the WHO, the overuse and misuse of antibiotics in animals, humans, and plants are the main reasons for the development of drug-resistant pathogens. Antibiotic resistance makes infections hard to treat and makes medical treatments, including cancer chemotherapy and surgeries such as cesarean sections and hip replacements, riskier. The market for antibiotic therapies is witnessing strong growth, driven by the urgent demand for treatments that can counteract rising resistance to existing drugs.

When a person contracts an infection caused by antibiotic-resistant bacteria, managing the illness becomes more challenging because fewer antibiotics can effectively treat the infection. In addition, these resistant bacteria can be transmitted to others, increasing the risk of wider spread. There are some rare instances where very few treatment options may be available.

U.S. Antibiotic Resistance Market Report Segmentation

This report forecasts revenue at the country level and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, the analyst has segmented the U.S. Antibiotic Resistance Market report based on disease, pathogen, drug class, mechanism of action, and distribution channel:
  • Disease Outlook (Revenue in USD Million, 2018 - 2030)
  • cUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI
  • Pathogen Outlook (Revenue in USD Million, 2018 - 2030)
  • E. coli
  • klebsiella pneumoniae
  • P. aeruginosa
  • S. aureus
  • baumannii
  • Strep. Pneumoniae
  • H. influenzae
  • CDI
  • Enterococcus fecium
  • Drug Class Outlook (Revenue in USD Million; 2018 - 2030)
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Combination therapies
  • Cephalosporins
  • Others
  • Mechanism of Action Outlook (Revenue in USD Million; 2018 - 2030)
  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others
  • Distribution Channel Outlook (Revenue in USD Million; 2018 - 2030)
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Pathogen
1.2.3. Drug Class
1.2.4. Mechanism of Action
1.2.5. Distribution Channel
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. Pathogen outlook
2.2.3. Drug Class outlook
2.2.4. Mechanism of Action
2.2.5. Distribution Channel
2.3. Competitive Insights
Chapter 3. U.S. Antibiotic Resistance Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
Chapter 4. U.S. Antibiotic Resistance Market Analysis Tools
4.1. Industry Analysis - Porter’s
4.1.1. Supplier power
4.1.2. Buyer power
4.1.3. Substitution threat
4.1.4. Threat of new entrant
4.1.5. Competitive rivalry
4.2. PESTEL Analysis
4.2.1. Political landscape
4.2.2. Technological landscape
4.2.3. Economic landscape
4.3. U.S. Antibiotic Resistance Market: Pipeline Analysis
Chapter 5. U.S. Antibiotic Resistance Market: Disease Estimates & Trend Analysis
5.1. Disease Segment Dashboard
5.2. U.S. Antibiotic Resistance Market: Disease Movement Analysis
5.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
5.4. cUTI
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. CDI
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. ABSSSI
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. HABP
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. CABP
5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.9. cIAI
5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.10. BSI
5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis
6.1. Pathogen Segment Dashboard
6.2. U.S. Antibiotic Resistance Market: Pathogen Movement Analysis
6.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
6.4. E. coli
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. klebsiella pneumoniae
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. P. aeruginosa
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.7. S. aureus
6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.8. A. baumannii
6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.9. Strep. Pneumoniae
6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.10. H. influenzae
6.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.11. CDI
6.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.12. Enterococcus fecium
6.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis
7.1. Drug Class Segment Dashboard
7.2. U.S. Antibiotic Resistance Market: Drug Class Movement Analysis
7.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
7.4. Oxazolidinones
7.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
7.5. Lipoglycopeptides
7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Tetracyclines
7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Combination therapies
7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Cephalosporins
7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.9. Others
7.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis
8.1. Mechanism of Action Segment Dashboard
8.2. U.S. Antibiotic Resistance Market: Mechanism of Action Movement Analysis
8.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
8.4. Protein Synthesis Inhibitors
8.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
8.5. Cell Wall Synthesis Inhibitors
8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.6. RNA Synthesis Inhibitors
8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.7. DNA Synthesis Inhibitors
8.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Others
8.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. U.S. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis
9.1. Distribution Channel Segment Dashboard
9.2. U.S. Antibiotic Resistance Market: Distribution Movement Analysis
9.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
9.4. Retail Pharmacies
9.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
9.5. Hospital Pharmacies
9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
9.6. Online Pharmacies
9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. Key company heat map analysis, 2024
10.4. Company Profiles
10.4.1. Melinta Therapeutics
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Merck & Co., Inc.
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. Melinta Therapeutics LLC
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Theravance Biopharma.
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Paratek Pharmaceuticals, Inc.
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Seres Therapeutics
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. AbbVie Inc.
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviations
Table 2 U.S. Antibiotic Resistance market, by Disease, 2018 - 2030 (USD Million)
Table 3 U.S. Antibiotic Resistance market, by Pathogen, 2018 - 2030 (USD Million)
Table 4 U.S. Antibiotic Resistance market, by Drug Class, 2018 - 2030 (USD Million)
Table 5 U.S. Antibiotic Resistance market, by Mechanism of Action, 2018 - 2030 (USD Million)
Table 6 U.S. Antibiotic Resistance market, by Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. antibiotic resistance market: market outlook
Fig. 10 U.S. antibiotic resistance competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. antibiotic resistance market driver impact
Fig. 16 U.S. antibiotic resistance market restraint impact
Fig. 17 U.S. antibiotic resistance market strategic initiatives analysis
Fig. 18 U.S. antibiotic resistance market: Disease movement analysis
Fig. 19 U.S. antibiotic resistance market: Disease outlook and key takeaways
Fig. 20 cUTI market estimates and forecast, 2018 - 2030
Fig. 21 CDI estimates and forecast, 2018 - 2030
Fig. 22 ABSSSI market estimates and forecast, 2018 - 2030
Fig. 23 HABP market estimates and forecast, 2018 - 2030
Fig. 24 CABP market estimates and forecast, 2018 - 2030
Fig. 25 cIAI estimates and forecast, 2018 - 2030
Fig. 26 BSI estimates and forecast, 2018 - 2030
Fig. 27 U.S. antibiotic resistance market: Pathogen movement analysis
Fig. 28 U.S. antibiotic resistance market: Pathogen outlook and key takeaways
Fig. 29 E. coli market estimates and forecasts, 2018 - 2030
Fig. 30 klebsiella pneumoniae market estimates and forecasts, 2018 - 2030
Fig. 31 P. aeruginosa market estimates and forecasts, 2018 - 2030
Fig. 32 S. aureus market estimates and forecasts, 2018 - 2030
Fig. 33 A. baumannii market estimates and forecasts, 2018 - 2030
Fig. 34 Strep. Pneumoniae market estimates and forecasts, 2018 - 2030
Fig. 35 H. influenzae market estimates and forecasts, 2018 - 2030
Fig. 36 CDI market estimates and forecasts, 2018 - 2030
Fig. 37 Enterococcus fecium market estimates and forecasts, 2018 - 2030
Fig. 38 U.S. antibiotic resistance market: Drug class movement analysis
Fig. 39 U.S. antibiotic resistance market: Drug class outlook and key takeaways
Fig. 40 Oxazolidinones market estimates and forecasts, 2018 - 2030
Fig. 41 Lipoglycopeptides market estimates and forecasts, 2018 - 2030
Fig. 42 Tetracyclines market estimates and forecasts, 2018 - 2030
Fig. 43 Combination therapies market estimates and forecasts, 2018 - 2030
Fig. 44 Cephalosporins market estimates and forecasts, 2018 - 2030
Fig. 45 Others market estimates and forecasts, 2018 - 2030
Fig. 46 U.S. antibiotic resistance market: Mechanism of action movement analysis
Fig. 47 U.S. antibiotic resistance market: Mechanism of action outlook and key takeaways
Fig. 48 Protein synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 49 Cell wall synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 50 RNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 51 DNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
Fig. 52 Others market estimates and forecasts, 2018 - 2030
Fig. 53 U.S. antibiotic resistance market: Distribution channel movement analysis
Fig. 54 U.S. antibiotic resistance market: Distribution channel outlook and key takeaways
Fig. 55 Retail pharmacies market estimates and forecasts, 2018 - 2030
Fig. 56 Hospital pharmacies market estimates and forecasts, 2018 - 2030
Fig. 57 Online pharmacies market estimates and forecasts, 2018 - 2030

Companies Mentioned

  • Melinta Therapeutics
  • Merck & Co., Inc.
  • Melinta Therapeutics LLC
  • Theravance Biopharma.
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics
  • AbbVie Inc.

Table Information

Report AttributeDetails
No. of Pages80
PublishedJuly 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.09 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.99 Billion
Compound Annual Growth Rate4.4%
Regions CoveredUnited States
No. of Companies Mentioned7

Related Topics

Related Reports

Antibiotic Resistance Market Size, Share & Trends Analysis Report by Disease (cUTI, CDI), Pathogen, Drug Class, Mechanism of Action, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Antibiotic Resistance Market Size, Share & Trends Analysis Report by Disease (cUTI, CDI), Pathogen, Drug Class, Mechanism of Action, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 120 Pages
  • Global
From
Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Fluoroquinolone), By Type (Branded Antibiotics, Generic Antibiotics), By Action Mechanism, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Fluoroquinolone), By Type (Branded Antibiotics, Generic Antibiotics), By Action Mechanism, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • Global
From
U.S. Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Cell Wall, Protein, DNA, RNA), By Type (Branded Antibiotics, Generic Antibiotics), By Drug Class (Cephalosporins, Penicillin, Carbapenems), And Segment Forecasts, 2025 - 2030 - Product Image

U.S. Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Cell Wall, Protein, DNA, RNA), By Type (Branded Antibiotics, Generic Antibiotics), By Drug Class (Cephalosporins, Penicillin, Carbapenems), And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • United States
From
Europe Antibiotics Market Size, Share & Trends Analysis Report by Drug Class (Cephalosporin, Penicillin), Type (Branded Antibodies, Generic Antibodies), Action Mechanism, Country, and Segment Forecasts, 2024-2030 - Product Image

Europe Antibiotics Market Size, Share & Trends Analysis Report by Drug Class (Cephalosporin, Penicillin), Type (Branded Antibodies, Generic Antibodies), Action Mechanism, Country, and Segment Forecasts, 2024-2030

  • Report
  • 80 Pages
  • Europe
From
Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Peptide Antibiotics Market Size, Share & Trends Analysis Report By Disease (Skin Infection, HABP/VABP), By Route of Administration (Injectable, Oral), By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.